Geode Capital Management LLC raised its stake in shares of Advaxis, Inc. (NASDAQ:ADXS) by 4.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 279,812 shares of the biotechnology company’s stock after buying an additional 12,736 shares during the period. Geode Capital Management LLC’s holdings in Advaxis were worth $2,286,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. MARSHALL WACE ASIA Ltd acquired a new position in shares of Advaxis during the first quarter valued at about $2,455,000. Marshall Wace North America L.P. acquired a new position in shares of Advaxis during the first quarter valued at about $2,455,000. FMR LLC increased its position in shares of Advaxis by 4.5% in the first quarter. FMR LLC now owns 4,287,780 shares of the biotechnology company’s stock valued at $35,031,000 after buying an additional 184,895 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock valued at $13,587,000 after buying an additional 139,710 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in shares of Advaxis by 116.3% in the first quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock valued at $707,000 after buying an additional 46,559 shares during the last quarter. Hedge funds and other institutional investors own 53.45% of the company’s stock.
Advaxis, Inc. (ADXS) traded down 2.04% during midday trading on Friday, hitting $6.24. The stock had a trading volume of 256,570 shares. The company’s market capitalization is $252.48 million. Advaxis, Inc. has a 52 week low of $5.70 and a 52 week high of $12.66. The company’s 50-day moving average price is $6.50 and its 200 day moving average price is $7.68.
Several equities analysts have issued reports on ADXS shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $19.00 price objective on shares of Advaxis in a research report on Wednesday, May 31st. HC Wainwright set a $23.00 price objective on Advaxis and gave the company a “buy” rating in a research report on Wednesday, June 14th. ValuEngine downgraded Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, BidaskClub downgraded Advaxis from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $22.00.
About Advaxis
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
